Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 15/20 | 0.54 |
| ▸ | MMP3 | P08254 | 4/20 | 0.54 |
| ▸ | MMP9 | P14780 | 2/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556573 | 0.90 | MME (0.49) | MMP1MMP3MMP9ADAM17ANPEP | |
| SCHEMBL28221966 | 0.87 | MMP1 (0.60) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL28221962 | 0.87 | MMP1 (0.60) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL28222036 | 0.87 | MMP1 (0.60) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL5557445 | 0.83 | OPRD1 (0.48) | — | |
| SCHEMBL17147126 | 0.83 | NPY4R (0.59) | — | |
| SCHEMBL5558798 | 0.82 | MMP1 (0.74) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL5552838 | 0.82 | FCER2 (0.48) | MMP1MMP3MMP2MMP7 | |
| SCHEMBL9417269 | 0.81 | MMP1 (0.54) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL12057953 | 0.81 | LTA4H (0.62) | MMP1MMP3MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MMP1 950/4885MMP3 327/4885MMP9 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.